ABBV AbbVie
- 162.360
- +1.550+0.96%
AbbVie News
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%. Currently, AbbVie has a market capitalization of $28
CVS Stresses 'Margins Over Membership' to Offset Medicare Pressure
Here Is What to Know Beyond Why AbbVie Inc. (ABBV) Is a Trending Stock
Express News | NYSE Order Imbalance 125408.0 Shares on Sell Side
Express News | CNBC Halftime Report Final Trades: Amazon.Com, RTX, AbbVie
Despite Lower Earnings Than Five Years Ago, AbbVie (NYSE:ABBV) Investors Are up 156% Since Then
It might be of some concern to shareholders to see the AbbVie Inc. (NYSE:ABBV) share price down 11% in the last month. But that doesn't change the fact that the returns over the last five years hav
Genstar Names Keith Martino to Strategic Advisory Board
Experienced Pharma Executive to Advise on the Firm's Healthcare Investments SAN FRANCISCO, April 30, 2024 /PRNewswire/ -- Genstar Capital, a leading private equity firm focused on investments in targ
Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Express News | Abbvie Inc. : Barclays Cuts Target Price to $187 From $195
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)
Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects
AbbVie Reinforces Commitment to Science and Innovation With a €150 Million Euro Investment in New Cutting-Edge Research and Development Facility in Germany
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance of
Express News | NYSE Order Imbalance 99441.0 Shares on Buy Side
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
In the latest quarter, 8 analysts provided ratings for AbbVie (NYSE:ABBV), showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent ratings, showcasing
Express News | BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 11.93% BMO Capital $195 → $180 Maintains Outperform 03/27/2024 21.26% Barclays $185 → $195 Main
These Pharmaceutical Firms Are on Sale: AbbVie, Pfizer, and Gilead
Barclays Adjusts Price Target on AbbVie to $187 From $195
AbbVie (ABBV) has an average rating of outperform and price targets ranging from $161 to $206, according to analysts polled by Capital IQ. Price: 159.60, Change: -0.02, Percent Change: -0.01
Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)
Buy Rating Affirmed: AbbVie's Strong Performance and Positive Growth Outlook
Analysis
Price Target
No Data
